Drug Trial Radar · NCT05673902
Study of the Safety and Efficacy of RPH-104 in Preventing Recurrences in Patients With Idiopathic Recurrent Pericarditis
Last checked: Nov 20, 2026Latest source record: Nov 15, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
17
Actual
Start
Dec 11, 2020
Primary completion
Jan 2026
Study completion Jan 2026
Sponsor
- Lead sponsor
- R-Pharm International, LLCIndustry
- Sponsor type
- Industry
- Collaborators
- R-Pharm; Unimed Laboratories; Data Management 365; Exacte Labs LLC
- First posted
- Jan 6, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate the safety and efficacy of RPH-104 for long-term use in a population of patients with idiopathic recurrent pericarditis who completed the main study CL04018068. The primary objective of the study is to evaluate the safety of RPH-104 80 mg once every 2 weeks in patients with idiopathic recurrent pericarditis who completed the main study.
Conditions
- Idiopathic Recurrent Pericarditis
Interventions
RPH-104Biological
solution for subcutaneous administration 40 mg/mL, 2 mL in the 4-mL glass vial
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events (AEs), by System Organ Class and Preferred TermTime frame: Up to week 228
- Incidence of Treatment-Emergent Serious Adverse Events (SAEs), by System Organ Class and Preferred TermTime frame: Up to week 228
- Incidence of Treatment-Emergent Adverse Events of Special Interest (AESI), by System Organ Class and Preferred TermTime frame: Up to week 228
- Incidence rate for serious adverse events (SAEs)Time frame: Up to week 228
- Incidence rate for adverse events of special Interest (AESI)Time frame: Up to week 228
Locations
1 site in 1 country. Site status is shown where the registry gives one.
National medical research center named after V. A. Almazov
Saint Petersburg, Russia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.